Alvin Shih, M.D. has been appointed executive vice president of R&D at Retrophin. Dr. Shih will oversee all medical, clinical and research functions. He joins the company from Pfizer, where he served as chief operating officer of the Rare Disease Research Unit, responsible for strategic initiatives and operational functions of the Unit.
Dr. Shih previously served as senior engagement manager for L.E.K. Consulting, LLC, where he provided strategic counsel on M&A transactions and growth development to life sciences companies.
“I am delighted to welcome Alvin to the Retrophin team in this very important leadership position,” said Martin Shkreli, founder and chief executive officer of Retrophin. “His rare disease R&D experience and business acumen will be invaluable as we continue to advance and grow our pipeline of drugs for patients suffering from serious diseases that currently have no viable treatment options.”